Market Overview

Portola Announces FDA Drug Application Acceptance, Sets Up For A Pivotal Year Ahead

Portola Announces FDA Drug Application Acceptance, Sets Up For A Pivotal Year Ahead
Related PTLA
50 Biggest Movers From Monday
The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

Portola Pharmaceuticals Inc (NASDAQ: PTLA) announced the FDA acceptance of the new drug application and European Medicines Agency validation of the marketing authorization for betrixaban for use in acute medically ill patients. With this news, the application’s probability of success has increased,” Credit Suisse’s Vamil Divan said in a report.

Divan maintains a Neutral rating on the company, while raising the price target from $20 to $29.

Increase In POS

Betrixaban now has a "fast track" status. The FDA has assigned priority review for the application, with an action date set for June 24, 2017.

Divan increased the probability of success assumption for the product from 40 percent to 65 percent, saying, “The general understanding the FDA must already have of the APEX study results and the support the drug seems to have both with officials at the FDA and with thought leaders in the community.”

A Pivotal Year Ahead

The betrixaban Prescription Drug User Fee Act date of June 24, 2017, is the most important catalyst in the list of “several important catalysts” Portola Pharma has over the next 12 months, the analyst commented.

The FDA will hold an Advisory Committee meeting to discuss the betrixaban application in Q2. Although this is based on a single Phase 3 study that almost missed the primary endpoint, “the totality of the data remains encouraging,” Johnson noted. He expects the company to resubmit their application for andexanet alfa, a novel anticoagulant, in Q2, with a potential approval by yearend 2017.

Latest Ratings for PTLA

Nov 2018Credit SuisseMaintainsNeutralNeutral
Oct 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight
Aug 2018Credit SuisseUpgradesUnderperformNeutral

View More Analyst Ratings for PTLA
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News Health Care Price Target Reiteration FDA Analyst Ratings Best of Benzinga


Related Articles (PTLA)

View Comments and Join the Discussion!

Latest Ratings

CNPRBC CapitalUpgrades34.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

A Tale Of 2 Banks: JPMorgan Surrendered To The Attorney General, Barclays Chose War

The 140-Year-Old Holiday Tradition On The NYSE Floor You Probably Don't Know